Author： Kam L.Y. Targan S.R.
Publisher： Informa Healthcare
ISSN： 1465-6566
Source： Expert Opinion on Pharmacotherapy, Vol.1, Iss.4, 2000-05, pp. : 615-622
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
New medical therapies that inhibit the bioactivity of TNF- represent a major breakthrough in the treatment of Crohn’s disease (CD). Anti-TNF-, monoclonal, chimeric antibody (infliximab) is now FDA approved for use in patients with active CD. Other investigational drugs that also inhibit TNF- activity include new ‘humanised’ anti-TNF- antibodies (CDP571), thalidomide, new analogues of thalidomide, and TNF- receptor fusion proteins. This review will summarise the key clinical data for each of these categories of TNF- inhibition and discuss the potential economic impact of these new compounds on the cost of CD management.
Related content
Anti-TNF agents in Crohn’s disease
Expert Opinion on Investigational Drugs, Vol. 9, Iss. 1, 2000-01 ,pp. :
Access to resources
Recommend
